期刊論文| 1. | De Leon, J.、Sandson, N. B.、Cozza, K. L.(2008)。A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II。Psychosomatics，49，347-361。   |
| 2. | Almoguera, B.、Riveiro-Alvarez, R.、Lopez-Castroman, J.(2013)。CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment。Pharmacogenetics and Genomics，23，627-630。 |
| 3. | de Leon, J.、Diaz, F. J.(2005)。A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors。Schizophrenia Research，76，135-157。 |
| 4. | Spina, E.、de Leon, J.(2007)。Metabolic drug interactions with newer antipsychotics: a comparative review。Basic & Clinical Pharmacology & Toxicology，100，4-22。 |
| 5. | Fmg, J.、Bouriti, M.、Baker, G. B.(1999)。Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4。Naunyn-Schmiedeberg's Archives of Pharmacology，359，147-151。 |
| 6. | Desai, H.、Seabolt, J.、Jann, M.(2001)。Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective。CNS Drugs，15，469-494。 |
| 7. | Tolson, A. H.、Wang, H.(2010)。Regulation of drug-metabolizing enzymes by xenobiotic receptors。PXR and CAR. Advanced Drug Delivery Reviews，62，1238-1249。 |
| 8. | Whitlock, J. P.(1999)。Induction of cytochrome P4501A1。Annual Review of Pharmacology and Toxicology，39，103-125。 |
| 9. | Miksys, S.、Tyndale, R. F.(2013)。2011 CCNP Heinz Lehmann Award paper: Cytochrome P450-mediated drug metabolism in the brain。Journal of Psychiatry & Neuroscience，38，152-163。 |
| 10. | Zevin, S.、Bcnowitz, N. L.(1999)。Drug interactions with tobacco smoking, an update。Clinical Pharmacokinetics，36，425-438。 |
| 11. | Lamba, V.、Yasuda, K.、Lamba, J. K.(2004)。PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators。Toxicology and Applied Pharmacology，199，251-265。 |
| 12. | Linnet, K.、Ejsing, T. B.(2008)。A review on the impact of P-glycoprotein on the penetration of drugs into the brain: focus on psychotropic drugs。European Neuropsychopharmacology，18，157-169。 |
| 13. | Zhu, H. J.、Wang, J. S.、Markowitz, J. S.(2007)。Risperidone and paliperidone inhibit p-glycoprotein activity in vitro。Neuropsychophannacol，32，757-764。 |
| 14. | Chiu, Y. H.、Lee, T. H.、Shen, W. W.(2007)。Use of low-dose topiramate in substance use disorder and bodyweight control。Psychiatry and Clinical Neurosciences，61(6)，630-633。 |
| 15. | Donaihy, A. B.、Kelly, T. M.、Sullivan, C.(2013)。Medications for substance use disorders。Social Work in Public Health，28，264-278。 |
| 16. | Gonzales, D.、Rennard, S. I.、Nides, M.(2006)。Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial。JAMA，296，47-55。 |
| 17. | Johnson, B. A.、Ait-Daoud, N.、Akhtar, F. Z.(2005)。Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial。Archives of Internal Medicine，165，1600-1605。 |
| 18. | de Leon, J.、Armstrong, S. C.、Cozza, K. L.(2005)。The dosing of atypical antipsychotics。Psychosomatics，46，262-273。 |